Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Apellis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Apellis Pharmaceuticals serves clients worldwide.
Website: apellis.com



Growth: Bad revenue growth rate -6.1%, there is slowdown compared to average historical growth rates 112.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +12.7%. On average the margin is decreasing steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.11 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 12.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 7.8% higher than minimum and 96.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.2x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: APLS
Share price, USD:  (-0.6%)3.6
year average price 21.25  


year start price 18.83 2025-06-13

max close price 41.05 2026-05-13

min close price 3.34 2026-06-08

current price 3.60 2026-06-12
Common stocks: 107 196 299

Dividend Yield:  0.0%
FCF Yield LTM: 12.9%
EV / LTM EBITDA: 3.1x
EV / EBITDA annualized: 7.6x
Last revenue growth (y/y):  -6.1%
Last growth of EBITDA (y/y):  -66.7%
Historical revenue growth:  +112.4%
Historical growth of EBITDA:  +27.8%
EV / Sales: 0.4x
Margin (EBITDA LTM / Revenue): 12.7%
Fundamental value created in LTM:
Market Cap ($m): 388
Net Debt ($m): 8
EV (Enterprise Value): 396
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-21benzinga.com

Apellis Valuation Ignores Empaveli Potential, Says Analyst

2026-01-17247wallst.com

Is Apellis Pharmaceuticals' FDA Win Just the Beginning?

2026-01-12seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-03globenewswire.com

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

2025-11-12seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript

2025-10-30seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript

2025-10-30zacks.com

Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates

2025-09-30seekingalpha.com

Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

2025-08-14seekingalpha.com

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

2025-08-02seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-05 2024-08-01 2024-05-07 2023-11-01 2023-07-31 2023-05-04 2022-11-07
acceptedDate 2025-10-30 06:57:30 2025-07-31 06:52:59 2025-02-28 07:00:18 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20 2022-02-28 16:06:11 2021-02-25 16:01:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 459M 178M 781M 197M 200M 172M 397M 99M 95M 45M 75M 22M 67M 251M
costOfRevenue 25M 14M 118M 34M 24M 21M 59M 22M 8M 8M 6M 1M 5M 25M
grossProfit 434M 164M 664M 163M 176M 152M 338M 77M 87M 37M 70M 21M 61M 226M
grossProfitRatio 0.947 0.921 0.83 0.882 0.88 0.774 0.912 0.826 0.937
researchAndDevelopmentExpenses 68M 67M 328M 89M 78M 85M 354M 79M 96M 110M 387M 95M 421M 300M
generalAndAdministrativeExpenses 0 0 418M 0 0 0 501M 146M 111M 102M 277M 78M 177M 139M
sellingAndMarketingExpenses 0 0 83M 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 143M 131M 501M 122M 128M 129M 501M 146M 111M 102M 277M 78M 177M 139M
otherExpenses 0 0 0 0 24 000 -499 000 0 -603 000 -63 000 -277 000 -288 000 0 1M -501 000
operatingExpenses 211M 198M 829M 211M 206M 214M 855M 225M 207M 212M 664M 174M 598M 439M
costAndExpenses 235M 212M 946M 244M 229M 234M 914M 247M 215M 220M 670M 175M 603M 464M
interestIncome 4M 3M 13M 3M 3M 3M 21M 5M 6M 5M 9M 3M 418 000 4M
interestExpense 11M 11M 40M 13M 9M 7M 30M -7M 7M 8M 33M 8M 13M 30M
depreciationAndAmortization 339 000 446 000 2M 621 000 449 000 444 000 2M 405 000 410 000 6M 1M 3M 1M 859 000
ebitda 228M -30M -155M -44M -28M -62M -495M -148M -115M -170M -617M -150M -731M -312M
ebitdaratio 0.497 -0.169 -0.223 -0.145 -0.358 -1.495 -1.206 -3.781 -6.786
operatingIncome 223M -33M -165M -47M -29M -62M -517M -148M -120M -175M -595M -153M -536M -214M
operatingIncomeRatio 0.487 -0.186 -0.24 -0.147 -0.36 -1.495 -1.268 -3.904 -6.934
totalOtherIncomeExpensesNet -7M -8M -32M -10M -8M -4M -9M 8M -63 000 -2M -57M -38M -210M -129M
incomeBeforeTax 216M -42M -197M -57M -38M -66M -526M -140M -122M -177M -652M -191M -746M -343M
incomeBeforeTaxRatio 0.472 -0.234 -0.289 -0.188 -0.384 -1.412 -1.283 -3.958 -8.652
incomeTaxExpense 602 000 466 000 1M 592 000 114 000 170 000 2M 233 000 194 000 282 000 669 000 446 000 352 000 2M
netIncome 216M -42M -198M -57M -38M -66M -529M -140M -122M -178M -652M -191M -746M -345M
netIncomeRatio 0.47 -0.236 -0.292 -0.189 -0.385 -1.414 -1.285 -3.964 -8.672
eps 1.71 -0.33 -1.6 -0.46 -0.3 -0.54 -4.45 -1.17 -1.02 -1.56 -6.15 -1.75 -8.84 -4.59
epsdiluted 1.71 -0.33 -0.46 -0.3 -0.54 -1.17 -1.02 -1.56 -1.75
weightedAverageShsOut 126M 126M 124M 124M 124M 123M 119M 120M 119M 114M 106M 109M 84M 75M
weightedAverageShsOutDil 126M 126M 124M 124M 124M 123M 119M 120M 119M 114M 106M 109M 84M 75M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-27 2023-02-21 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -28M -9M -24M -13M -26M
ebit -156M -497M -619M -733M -313M
nonOperatingIncomeExcludingInterest -9M -20M 24M 196M 99M
netIncomeFromContinuingOperations -198M -529M -652M -746M -345M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -198M -529M -652M -746M -345M
epsDiluted -1.6 -4.45 -6.15 -8.84 -4.59

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-05 2024-08-01 2024-05-07 2023-11-01 2023-07-31 2023-05-04 2022-11-07
acceptedDate 2025-10-30 06:57:30 2025-07-31 06:52:59 2025-02-28 07:00:18 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20 2022-02-28 16:06:11 2021-02-25 16:01:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 479M 371M 411M 397M 361M 327M 351M 452M 616M 765M 552M 584M 640M 566M
shortTermInvestments 0 0 5M 0 8M 8M 1M 13M 9M 0 0 124M 61M 312M
cashAndShortTermInvestments 479M 371M 416M 397M 361M 327M 352M 452M 616M 765M 552M 709M 701M 878M
netReceivables 355M 229M 272M 284M 309M 268M 206M 187M 111M 32M 8M 8M 80M 25M
inventory 123M 121M 82M 121M 153M 161M 146M 99M 103M 85M 86M 60M 24M 0
otherCurrentAssets 34M 34M 9M 32M 37M 55M 22M 13M 27M 34M 37M 24M 14M 11M
totalCurrentAssets 991M 756M 789M 834M 860M 811M 766M 797M 893M 954M 720M 832M 824M 917M
propertyPlantEquipmentNet 22M 17M 19M 20M 20M 19M 21M 20M 22M 24M 25M 25M 26M 25M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 3M 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 46M 49M 77M 48M 24M 1M -2M 1M 827 000 793 000 16M 16M 32M 19M
totalNonCurrentAssets 68M 66M 96M 68M 45M 21M 22M 21M 23M 25M 41M 41M 58M 43M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 1 059M 821M 885M 902M 904M 832M 789M 818M 916M 979M 760M 873M 882M 961M
accountPayables 39M 54M 39M 43M 38M 27M 38M 18M 28M 31M 37M 14M 17M 8M
shortTermDebt 101M 7M 0 14M 12M 84M 0 6M 6M 6M 0 5M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 2M 2M 4M 0 117M 98M 0 0 0 0 0
otherCurrentLiabilities 140M 139M 0 133M 117M 101M 76M 45M 44M 101M 81M 96M 8M 4M
totalCurrentLiabilities 280M 201M 186M 191M 169M 215M 248M 186M 175M 139M 168M 115M 132M 128M
longTermDebt 375M 462M 453M 464M 468M 338M 93M 104M 105M 106M 93M 108M 189M 359M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 3M 2M 8M 10M 3M 12M 242M 296M 290M 322M 316M 431M 345M 254M
totalNonCurrentLiabilities 378M 464M 471M 473M 471M 350M 347M 400M 395M 428M 423M 450M 551M 628M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 21M 16M 17M 18M 17M 10M 18M 17M 18M 19M 20M 21M 21M 19M
totalLiabilities 658M 665M 657M 665M 640M 565M 594M 586M 570M 567M 590M 565M 683M 756M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 12 000 12 000 12 000 12 000 12 000 12 000 12 000 12 000 12 000 12 000 11 000 11 000 10000 8000
retainedEarnings -2 954M -3 170M -3 035M -2 999M -2 942M -2 904M -2 837M -2 749M -2 609M -2 487M -2 309M -2 143M -1 657M -926M
accumulatedOtherComprehensiveIncomeLoss -2M -3M -3M -3M -3M -4M -4M -1M -796 000 -775 000 -875 000 -3M -2M -116 999
othertotalStockholdersEquity 3 358M 3 329M 3 239M 3 209M 3 174M 2 982M 2 955M 2 900M 2 453M
totalStockholdersEquity 401M 156M 229M 237M 264M 267M 195M 232M 345M 412M 170M 307M 199M 205M
totalEquity 401M 156M 229M 237M 264M 267M 195M 232M 345M 412M 170M 307M 199M 205M
totalLiabilitiesAndStockholdersEquity 1 059M 821M 902M 904M 832M 818M 916M 979M 873M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 059M 821M 885M 902M 904M 832M 789M 818M 916M 979M 760M 873M 882M 961M
totalInvestments 0 0 5M 0 8M 8M 4M 13M 9M 0 0 124M 61M 312M
totalDebt 475M 470M 470M 470M 475M 431M 111M 110M 111M 112M 113M 113M 210M 378M
netDebt -4M 98M 58M 74M 113M 104M -240M -343M -505M -653M -439M -471M -430M -188M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-27 2023-02-21 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 272M 206M 8M 80M 25M
otherReceivables 0 0 0 0 0
prepaids 10M 39M 36M 5M 3M
totalPayables 39M 38M 37M 17M 8M
otherPayables 0 0 0 0 0
accruedExpenses 140M 128M 43M 103M 112M
capitalLeaseObligationsCurrent 7M 6M 6M 4M 4M
capitalLeaseObligationsNonCurrent 10M 11M 14M 17M 15M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 3 267M 3 036M 2 480M 1 857M 1 131M
otherTotalStockholdersEquity -1 0 0 -1 -1

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-05 2024-08-01 2024-05-07 2023-11-01 2023-07-31 2023-05-04 2022-11-07
acceptedDate 2025-10-30 06:57:30 2025-07-31 06:52:59 2025-02-28 07:00:18 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20 2022-02-28 16:06:11 2021-02-25 16:01:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 216M -42M -198M -57M -38M -66M -529M -140M -122M -178M -652M -191M -746M -345M
depreciationAndAmortization 339 000 446 000 2M 457 000 449 000 444 000 2M 405 000 410 000 399 000 1M 357 000 1M 859 000
deferredIncomeTax 0 0 0 0 0 0 0 133 000 0 0 0 0 198M 0
stockBasedCompensation 28M 27M 114M 27M 30M 30M 106M 22M 29M 29M 91M 24M 71M 45M
changeInWorkingCapital -136M 18M -18M 63M -6M -103M -200M -57M -64M -36M -16M -28M -94M 20M
accountsReceivables -131M 21M -58M 25M -37M -61M 0 -58M -79M -24M 2M -574 000 -10M 0
inventory 5M -26M -11M 9M -15M -15M 0 5M -18M 144 000 -69M -11M -16M 0
accountsPayables -16M -1M 1M -1M 11M -11M 170 000 -10M -4M -6M 19M -7M 10M -54 000
otherWorkingCapital 5M 24M 50M 30M 33M -16M -200M 6M 37M 29M 33M -9M -78M 20M
otherNonCashItems 636 000 614 000 12M 822 000 76M 124M 26M 6M 7M 7M 62M 41M 6M 119M
netCashProvidedByOperatingActivities 108M 4M -88M 34M -8M -133M -595M -169M -150M -178M -514M -154M -563M -160M
investmentsInPropertyPlantAndEquipment -148 000 -49 000 -403 000 0 -90 000 -293 000 -773 000 -47 000 -372 000 -259 000 -2M -196 000 -1M -5M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 -61M 0 -249M 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 -332M 0 -171M -879M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 393M 125M 420M 568M
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -148 000 -49 000 0 -90 000 -293 000 -47 000 -372 000 -259 000 125M
debtRepayment 0 0 0 0 -99M 0 -25M 0 0
commonStockIssued 797 000 7M -15M -99M 9M 6M 26M 384M 0
commonStockRepurchased 0 0 0 3M 0 -28 000 0 -11 000 -28 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 -2M 0 0
otherFinancingActivites -4000 0 3M 42M -28 000 -11 000 2M 7M 10M
netCashUsedProvidedByFinancingActivities 793 000 7M 3M 42M 108M 6M 2M 391M 10M
effectOfForexChangesOnCash 22 000 685 000 -659 000 173 000 342 000 -209 000 135 000 -458 000 -47 000 56 000 -488 000 -310 000 -2M 359 000
netChangeInCash 109M 12M 60M 37M 34M -25M -201M -164M -149M 213M -89M -20M 75M 215M
cashAtEndOfPeriod 481M 371M 413M 398M 361M 327M 352M 454M 617M 766M 553M 585M 642M 567M
cashAtBeginningOfPeriod 371M 360M 352M 361M 327M 352M 553M 617M 766M 553M 642M 606M 567M 352M
operatingCashFlow 108M 4M -88M 34M -8M -133M -595M -169M -150M -178M -514M -154M -563M -160M
capitalExpenditure -148 000 -49 000 -403 000 0 -90 000 -293 000 -773 000 -47 000 -372 000 -259 000 -2M -196 000 -1M -5M
freeCashFlow 108M 4M -88M 34M -8M -133M -596M -169M -151M -178M -515M -155M -564M -166M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-27 2023-02-21 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 99 000 61M 249M 0
netCashProvidedByInvestingActivities -403 000 -674 000 60M 248M -317M
netDebtIssuance 365M 0 0 0 323M
longTermNetDebtIssuance 365M 0 0 0 323M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 19M 384M 380M 380M 381M
netCommonStockIssuance 19M 384M 380M 380M 381M
commonStockIssuance 19M 384M 380M 380M 381M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -235M 10M -14M 12M -12M
netCashProvidedByFinancingActivities 149M 394M 366M 392M 692M
incomeTaxesPaid 2M 0 5M 49 000 0
interestPaid 29M 0 5M 10M 13M

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-08-02 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-31 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-07 22:01 ET
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
2026-03-31 ET
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
2026-03-31 ET
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
2026-03-02 ET
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
2026-02-24 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-23 ET
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-19 ET
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
2026-02-10 12:00 ET
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
2026-01-12 ET
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-05 ET
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-03 ET
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
2025-11-25 ET
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-11-12 ET
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
2025-11-05 ET
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
2025-10-30 11:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
2025-10-20 ET
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
2025-10-16 ET
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
2025-08-27 ET
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-07-31 ET
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
2025-07-28 ET
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
2025-07-24 ET
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
2025-07-01 ET
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
2025-06-06 ET
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
2025-06-04 ET
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-07 ET
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
2025-05-06 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2025-04-30 ET
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
2025-04-21 ET
Apellis Announces Craig Wheeler to Join the Board of Directors
2025-04-01 ET
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
2025-02-28 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-24 ET
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
2025-02-20 ET
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
2025-02-14 ET
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
2025-02-04 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-27 ET
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
2025-01-13 ET
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-10 ET
Apellis Announces Keli Walbert to Join the Board of Directors
2025-01-07 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-06 ET
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-06 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-27 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2024-11-12 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
2024-11-05 12:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
2024-10-26 18:00 ET
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
2024-10-22 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
2024-10-16 11:00 ET
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
2024-10-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-25 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
2024-09-20 09:00 ET
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
2024-09-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2024-08-08 11:29 ET
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
2024-08-08 11:00 ET
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
2024-08-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-01 11:05 ET
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
2024-07-18 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
2024-07-09 11:00 ET
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
2024-06-28 10:57 ET
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
2024-06-10 11:00 ET
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
2024-06-05 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-24 14:00 ET
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
2024-05-14 12:00 ET
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
2024-05-07 11:05 ET
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
2024-05-06 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
2024-05-01 11:00 ET
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2024-04-26 11:15 ET
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
2024-04-23 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
2024-04-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-01 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-11 11:00 ET
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
2024-03-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 12:05 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-26 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2024-02-20 12:00 ET
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024-02-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-26 12:06 ET
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
2024-01-08 14:00 ET
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
2024-01-05 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-02 12:00 ET
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-28 12:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
2023-12-14 12:00 ET
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
2023-12-11 12:00 ET
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
2023-12-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-21 12:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-04 17:37 ET
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
2023-11-01 11:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
2023-10-25 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
2023-10-20 12:00 ET
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
2023-10-17 11:00 ET
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
2023-10-05 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-05 11:00 ET
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
2023-10-05 ET
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
2023-10-02 11:00 ET
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
2023-09-25 11:30 ET
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
2023-09-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-30 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2023-08-29 10:58 ET
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
2023-08-22 20:43 ET
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
2023-08-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-31 11:00 ET
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
2023-07-30 17:00 ET
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
2023-07-29 18:52 ET
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
2023-07-24 13:00 ET
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
2023-07-10 11:00 ET
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
2023-07-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-07 11:00 ET
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-25 11:00 ET
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
2023-05-05 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 20:05 ET
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
2023-05-03 11:00 ET
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
2023-04-27 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
2023-04-23 22:05 ET
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
2023-04-21 11:00 ET
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
2023-04-17 11:00 ET
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
2023-04-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-01 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2023-02-27 22:19 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
2023-02-23 02:48 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2023-02-22 12:22 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2023-02-21 21:13 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-17 21:06 ET
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
2023-02-13 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-05 12:00 ET
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
2023-01-03 12:00 ET
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-16 12:00 ET
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
2022-12-07 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-22 21:05 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-11-18 12:00 ET
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
2022-11-07 21:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
2022-11-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-03 20:01 ET
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
2022-11-03 13:05 ET
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
2022-10-31 20:05 ET
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
2022-10-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-30 21:30 ET
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
2022-09-30 11:00 ET
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
2022-09-12 20:05 ET
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
2022-09-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-01 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-08-24 12:00 ET
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
2022-08-08 20:05 ET
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
2022-08-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-01 20:05 ET
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
2022-07-27 11:00 ET
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2022-07-19 11:00 ET
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
2022-07-14 14:01 ET
Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting
2022-07-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-22 11:00 ET
Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
2022-06-10 07:00 ET
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
2022-06-07 11:00 ET
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
2022-06-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-01 20:05 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-06-01 11:00 ET
Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
2022-05-12 15:05 ET
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
2022-05-06 20:23 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-05 20:05 ET
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
2022-05-04 20:05 ET
Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
2022-05-03 11:00 ET
Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
2022-05-02 19:30 ET
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
2022-04-26 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
2022-04-21 11:00 ET
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
2022-04-04 11:00 ET
Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
2022-03-28 20:01 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2022-03-24 11:00 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2022-03-23 20:02 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2022-03-16 11:00 ET
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
2022-03-02 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-02-28 21:05 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-22 12:00 ET
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
2022-01-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-03 12:00 ET
Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-15 12:20 ET
Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
2021-12-15 12:00 ET
Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
2021-12-13 16:45 ET
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
2021-11-29 12:00 ET
Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021-11-18 21:01 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2021-11-16 12:00 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2021-11-15 21:01 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2021-11-12 12:00 ET
Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback
2021-11-10 12:00 ET
Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting
2021-11-08 21:01 ET
Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
2021-11-04 13:17 ET
Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
2021-11-03 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-11-01 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
2021-10-15 11:36 ET
Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
2021-10-15 11:17 ET
Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
2021-10-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-30 15:49 ET
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
2021-09-20 11:00 ET
Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
2021-09-09 20:05 ET
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
2021-09-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-03 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer
2021-08-09 20:01 ET
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
2021-08-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-29 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
2021-07-26 11:00 ET
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-07-08 02:06 ET
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-07-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-06-30 20:15 ET
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
2021-06-23 11:00 ET
Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
2021-06-03 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-06-01 14:02 ET
Acuamark Diagnostics Welcomes Dr. Cedric Francois To Its Board of Directors
2021-05-25 11:54 ET
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
2021-05-25 11:00 ET
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
2021-05-14 22:25 ET
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2021-05-12 14:06 ET
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
2021-05-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-28 20:01 ET
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
2021-04-21 11:00 ET
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
2021-04-16 16:44 ET
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2021-04-13 11:00 ET
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
2021-03-17 23:39 ET
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
2021-03-17 21:48 ET
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
2021-03-10 14:15 ET
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
2021-03-05 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-03-04 21:05 ET
Apellis Provides Update on APL-9 for Severe COVID-19
2021-02-25 21:01 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-22 13:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-02-18 21:05 ET
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
2021-02-05 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-26 22:00 ET
Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-01-21 12:00 ET
Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
2021-01-07 11:55 ET
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-01-05 12:00 ET
Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-10 11:18 ET
Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH
2020-12-10 11:00 ET
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
2020-12-07 15:00 ET
Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
2020-12-04 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-30 12:00 ET
Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
2020-11-19 11:58 ET
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
2020-11-19 11:45 ET
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
2020-11-16 12:00 ET
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
2020-11-13 15:40 ET
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
2020-11-11 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2020-11-05 12:00 ET
Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
2020-11-02 12:00 ET
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
2020-10-27 11:00 ET
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
2020-10-19 11:00 ET
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
2020-10-15 11:00 ET
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
2020-10-09 14:14 ET
Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
2020-10-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-10-05 11:00 ET
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
2020-10-03 15:05 ET
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
2020-09-24 20:05 ET
Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
2020-09-21 20:05 ET
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
2020-09-15 11:00 ET
Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
2020-09-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-09-02 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2020-08-21 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-08-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-31 11:00 ET
Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
2020-07-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-07 11:00 ET
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
2020-07-02 12:00 ET
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-06-16 11:00 ET
Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
2020-06-12 06:30 ET
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
2020-06-10 21:34 ET
Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
2020-06-05 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-04 11:00 ET
Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
2020-05-29 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-28 11:00 ET
Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
2020-05-21 11:00 ET
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-05-14 14:55 ET
Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
2020-05-08 11:00 ET
Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
2020-05-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-07 11:24 ET
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
2020-04-29 20:11 ET
Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
2020-04-28 11:00 ET
Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
2020-04-06 12:00 ET
Paul Fonteyne Joins Apellis Board of Directors
2020-02-27 21:44 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26 12:00 ET
Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
2020-01-16 21:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-01-13 17:10 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2020-01-09 02:30 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2020-01-07 21:10 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-01-07 12:00 ET
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-01-02 12:00 ET
Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-26 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2019-11-15 22:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-08 15:00 ET
Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
2019-11-07 22:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-05 12:30 ET
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
2019-10-11 20:01 ET
Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
2019-10-04 21:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-27 21:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-26 12:00 ET
Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
2019-09-18 12:00 ET
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
2019-09-16 21:00 ET
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
2019-09-12 12:22 ET
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
2019-09-11 20:38 ET
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
2019-09-09 21:00 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-03-12 22:00 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-03-11 16:01 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2019-03-07 12:00 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SEC forms

Show financial reports only

SEC form 10
2026-05-07 10:56 ET
Apellis Pharmaceuticals published news for 2026 q1
SEC form 10
2026-02-24 06:56 ET
Apellis Pharmaceuticals reported for 2025 q4
SEC form 8
2026-01-12 21:52 ET
Apellis Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 21:52 ET
Apellis Pharmaceuticals published news for 2025 q4
SEC form 10
2025-10-30 10:57 ET
Apellis Pharmaceuticals reported for 2025 q3
SEC form 10
2025-07-31 10:52 ET
Apellis Pharmaceuticals reported for 2025 q2
SEC form 10
2025-05-07 11:01 ET
Apellis Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Apellis Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-28 12:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Apellis Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-05 06:57 ET
Apellis Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 07:02 ET
Apellis Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Apellis Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 07:02 ET
Apellis Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Apellis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-27 07:30 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:30 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 07:01 ET
Apellis Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-01 07:02 ET
Apellis Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Apellis Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-05 00:00 ET
Apellis Pharmaceuticals published news for 2023 q3
SEC form 10
2023-07-31 16:07 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-31 08:03 ET
Apellis Pharmaceuticals reported for 2023 q2
SEC form 8
2023-07-31 00:00 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 10
2023-07-31 00:00 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-17 16:14 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-01 16:10 ET
Apellis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Apellis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-21 00:00 ET
Apellis Pharmaceuticals reported for 2022 q4
SEC form 10
2022-11-07 00:00 ET
Apellis Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-08 00:00 ET
Apellis Pharmaceuticals reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
Apellis Pharmaceuticals reported for 2022 q1
SEC form 10
2022-02-28 00:00 ET
Apellis Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Apellis Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-08 00:00 ET
Apellis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-09 00:00 ET
Apellis Pharmaceuticals published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
Apellis Pharmaceuticals published news for 2021 q1